Table 5.

Interaction between pSS and cDDD group in bisphosphonate and non-bisphosphonate users.

	Case 1: bisphosphonate users		Case 2: non-bisphosphonate users
	ADJ. HR	95% CI	ADJ. HR	95% CI
pSS
No (Ref.)	1.000		1.000
Yes	2.509*	(1.141–5.515)	0.549	(0.145–2.076)
CDDD group
< 224(Ref.)	1.000		1.000
≥ 224	0.705	(0.385–1.292)	0.534	(0.262–1.089)
Interaction
pSS*cDDD group	0.701	(0.254–1.932)	1.117	(0.160–7.782)

(1) *0.01 ≤ p < 0.05, **0.0001 ≤ p < 0.01, ***p < 0.0001. (2) ^‡ADJ. HR was adjusted by sex, comorbidities, and age at the initiation of bisphosphonate use.

pSS primary Sjogren syndrome, cDDD cumulative dose with defined daily dose, 95% CI 95% confidence interval, ADJ. HR adjusted hazard ratio, Ref reference.